Annual report: surveillance of adverse events following immunisation in Australia, 2005
DOI:
https://doi.org/10.33321/cdi.2006.30.28Keywords:
AEFI, adverse events, vaccines, surveillance, immunisation, vaccine safetyAbstract
This report summarises Australian passive surveillance data for adverse events following immunisation (AEFI) reported to the Adverse Drug Reactions Advisory Committee for 2005, and describes reporting trends over the six year period 2000 to 2005. There were 839 AEFI records for vaccines received in 2005. This is an annual AEFI reporting rate of 4.1 per 100,000 population, the lowest since 2000 and a 22 per cent decrease compared with 2004 (1,081 records; 5.4 AEFI records per 100,000 population). The decrease was not consistent across age groups. Reporting of AEFI increased for children aged <1 year in 2005 (60.7 versus 50.3 per 100,000 population) and decreased for the 7 to <20 year age group (0.9 versus 8.9 per 100,000 population). Dose-based AEFI reporting rates in 2005 were 11.0 per 100,000 doses of scheduled vaccines for children aged <7 years and 2.0 per 100,000 doses of influenza vaccine for adults aged ≥18 years. The majority of records described non-serious events while 9 per cent (n=72) described AEFIs defined as serious. There was one report of death in an older person following influenza vaccine and one of non-polio acute flaccid paralysis in an infant, both temporally associated with immunisation. The most frequently reported individual AEFI was injection site reaction in children following a fifth dose of diphtheria-tetanus-acellular pertussis vaccine (79 reports per 100,000 doses). The increase in the population-based AEFI reporting rate for children aged <1 year in 2005 coincided with the introduction of national immunisation programs for conjugate pneumococcal vaccine in January 2005 and inactivated poliovirus vaccine in November 2005. The fall in reporting rates for older children and adolescents follows the completion of the national meningococcal C catch-up program in early 2005. The consistently low reporting rate of serious AEFIs demonstrates the high level of safety of vaccines in Australia. Commun Dis Intell 2006;30:319–334.
Downloads
References
Mansoor O, Shin S, Maher C, and the Immunization Focus of WPRO. Immunization safety surveillance: guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. Manila: World Health Organization Regional Office for the Western Pacific; 1999.
Duclos P. A global perspective on vaccine safety. Vaccine 2004;22:2059–2063.
Chen RT, Destefano F, Pless R, Mootrey G, Kramarz P, Hibbs B. Challenges and controversies in immunization safety. Infect Dis Clin North America 2001;15:21–39.
National Health and Medical Research Council. The Australian Immunisation Handbook. 8th edn. Canberra: Australian Government Printing Service; 2003.
Uppsala Monitoring Centre. WHO Collaborating Centre for International Drug Monitoring. Available from: http://www.who-umc.org Accessed on 26 July 2006.
Lawrence GL, Menzies R, Burgess M, McIntyre P, Wood N, Boyd I, et al. Adverse events following immunisation: Australia 2000–2002. Commun Dis Intell 2003;27:307–323.
Lawrence G, Boyd I, McIntyre P, Isaacs D. Surveillance of adverse events following immunisation: Australia 2002–2003. Commun Dis Intell 2004;28:324–323
Lawrence G, Boyd I. Adverse events following immunisation for children aged less than 7 years, 1 January to 30 June 2004. Commun Dis Intell 2004;28:324–323.
Lawrence G, Boyd I, McIntyre P, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2004. Commun Dis Intell 2005;29:248–262. Erratum Commun Dis Intell 2005;29:416.
Lawrence G, Boyd I. Supplementary report: surveillance of adverse events following immunisation for children aged less than 7 years in Australia, 1 January to 30 June 2005. Commun Dis Intell 2005;29:413–416.
Australian Government Department of Health and Ageing. Immunisation programs and initiatives. Available from: http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/programs Accessed on 25 July 2006.
Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)—United States, 1991–2001. MMWR Surveill Summ 2003;52:1–24. Erratum MMWR Morb Mortal Wkly Rep 2003;52:113.
Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Safety 1999;20:109–117.
The SAS system for Windows [computer program]. Version 9.1.3. Cary, NC: SAS Institute Inc.; 2005.
Australian Institute of Health and Welfare. 2004 influenza vaccine survey: summary results. Canberra: Australian Institute of Health and Welfare, 2005.
Australian Government Department of Health and Ageing. Additional reports—Childhood immunisation coverage. Commun Dis Intell 2006;30:xx
Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun MM, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatric Infect Dis J 2004;23:287–294.
Stambos V, Brussen K, Thorley B. Annual report of the Australian National Poliovirus Reference Laboratory, 2004. Commun Dis Intell 2005;29:263–268.
Wise R, Iskander J, Pratt R, Campbell S, Ball R, Pless R, et al. Post licensure safety surveillance for 7–valent pneumococcal conjugate vaccine. JAMA 2004;292:1702–1710.
Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000;284:1271–1279. Erratum JAMA 2000;284:3129.
Rennels MB, Deloria MA, Pichichero ME, Losonky GA, Englund JA, Meade B, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000;105:e12.
Gold MS, Noonan S, Osbourn M, Precepa S, Kempe AE. Local reactions after the fourth dose of acellular pertussis vaccine in South Australia. Med J Aust 2003;179:191–194.
Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243–248.
Jackson LA, Nelson JC, Whitney CG, Neuzil KM, Benson P, Malais D, et al. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population. Vaccine 2006;24;151–156.
Brotherton J, McIntyre P, Puech M, Wang H, Gidding H, Hull B, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2001–2002. Commun Dis Intell 2004;28 Suppl 2:i–S116.
Yohannes K, Roche P, Roberts A, Liu C, Firestone SM, Bartlett M, et al. Australia’s notifiable diseases status, 2004: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2006;30:1–79.
Horby P, Gilmour R, Wang H, McIntyre P. Progress towards eliminating Hib in Australia: An evaluation of Haemophilus influenzae type b prevention in Australia, 1 July 1993 to 30 June 2000. Commun Dis Intell 2003;27:324–41.
Roche P, Krause V, Bartlett M, Coleman D. Invasive pneumococcal disease in Australia, 2003. Commun Dis Intell 2004;28:441–454.
The Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2004. Commun Dis Intell 2005;29:149–158.
Downloads
Published
How to Cite
License
Copyright (c) 2006 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
